TITLE

The Industry

PUB. DATE
October 2006
SOURCE
Pharmaceutical Representative;Oct2006, Vol. 36 Issue 10, p10
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on developments related to pharmaceuticals industry. Eli Lilly & Co., Indianapolis, and Fort Worth, Texas-based Alcon Inc. have made an agreement to co-promote Lilly's Arxxant in the U.S. and Puerto Rico. Neurocrine Biosciences has laid off its field sales organization of about 200 after delays in gaining FDA approval and the discontinuation of a collaboration agreement with New York-based Pfizer Inc. Pfizer Inc., has received conditional approval to market Sutent.
ACCESSION #
23222422

 

Related Articles

  • Neurocrine sheds 200 Indiplon reps. S. M. // Medical Marketing & Media;Sep2006, Vol. 41 Issue 9, p26 

    The article reports on Neurocrine Biosciences' decision to lay off its entire 200-person sales force. Pfizer has ended its marketing partnership with Neurocrine after the latter lost approval for insomnia drug Indiplon. Pfizer also lost its U.S. patent protection for Zoloft. Neurocrine has been...

  • NEW INDICATIONS.  // Drug Topics;8/18/2003, Vol. 147 Issue 16, p68 

    Presents news briefs related to pharmaceutical industry in the U.S. as of August 2003. Eli Lilly and Co.'s receipt of approval of novel indication for its growth hormone Humatrope; Food and Drug Administration's approval of Zyvox from Pfizer Inc. for the treatment of diabetic foot infection.

  • Lilly kicks lobbying into high gear.  // Indianapolis Business Journal;7/6/2009, Vol. 30 Issue 18, p13 

    The article reports on the amount spent by Eli Lilly and Co. for lobbying efforts in Indianapolis, Indiana. It is noted that Eli Lilly spent $12.5 million in leading all pharmaceutical companies for lobbying efforts and ranks 12th among all corporations in the U.S. where it has spent $3.4...

  • TOP STORIES.  // MondayMorning;1/19/2009, Vol. 17 Issue 2, p1 

    The article offers U.S. news briefs related to pharmaceutical and medical supplies industry. Eli Lilly & Co. will plead guilty to a charge of promoting its antipsychotic drug Zyprexa for unapproved uses. Pfizer Inc. may fire almost a third of its U.S. sales force, or as many as 2400 workers, in...

  • Finding API Opportunity in the Pharmaceutical Pipeline. Sauer, Pamela // Chemical Market Reporter;10/08/2001, Vol. 260 Issue 13, pFR 22 

    Reports on the products that can be expected from pharmaceutical firms in 2002 and beyond. Promising drugs from Eli Lilly that are in Phase III development or later; Products from Pfizer; Products that Pharmacia will soon release.

  • Pfizer: Unlikely To Bid for Neurocrine. Hamerman, Joshua // Mergers & Acquisitions Report;3/27/2006, Vol. 19 Issue 12, p1 

    Focuses on the disagreement of some analysts with the prediction that Pfizer Inc. will acquire Neurocrine Biosciences Inc. Drugs developed by Neurocrine; Projected value of Neurocrine if it is acquired by Pfizer, according to a Sanford C. Bernstein analyst; Factors that make it impossible for...

  • Neurocrine: indiplon set to wake up insomnia market.  // PharmaWatch: CNS;May 2004, Vol. 3 Issue 5, p5 

    Reports on the efficacy of Indiplon insomnia drug developed in partnership of Neurocrine Biosciences Inc. and Pfizer Inc. in the U.S. Significance of the drug to help insomnia patients fall asleep faster and longer with minimal disturbance; Composition of the drug with GABA neurotransmitter...

  • Wake Up Call for Sleep Category. Edwards, Jim // Brandweek;4/18/2005, Vol. 46 Issue 16, p5 

    Reports on several pharmaceutical companies that have launched and began advertising campaigns for their sleeping pills. Neurocrine Biosciences and Pfizer on Indiplon; Sepracor on Lunesta; Sanofi-Aventis on Ambien.

  • Neurocrine, Pfizer to Stay Connected. Weeks, Katie // San Diego Business Journal;5/22/2006, Vol. 27 Issue 21, p1 

    The article reports that Pfizer Inc., a pharmaceutical industry has announced that it will not cut its relationship with Neurocrine Biosciences (NB) Inc., a biotechnology industry despite of the rejection of the U.S. Food and Drug Administration (FDA) on their co-developed indiplon sleeping...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics